[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336964-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336964-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","breaking-the-shield-of-solid-tumors-a-combined-approach-for-enhanced-efficacy-of-car-t-cells","Breaking the Shield of Solid Tumors - a Combined Approach for Enhanced Efficacy of CAR-T Cells","","Chimeric antigen receptor (CAR)-T cell therapy expands cancer treatment options, showing strong efficacy for blood cancers, yet encounters major limitations against solid tumors. Key barriers include antigenic diversity and an immunosuppressive tumor microenvironment that hinders immune-cell penetration, alongside reduced CAR-T proliferation and cytotoxicity, and risks such as antigen loss and therapy-related toxicity. This review discusses strategies to overcome these challenges, and evaluates potential benefits of combining approaches that can increase tumor sensitivity to other agents.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/breaking-the-shield-of-solid-tumors-a-combined-approach-for-enhanced-efficacy-of-car-t-cells/336964/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/breaking-the-shield-of-solid-tumors-a-combined-approach-for-enhanced-efficacy-of-car-t-cells/336964.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is CAR-T therapy less effective in solid tumors than in blood cancers?","Question",{"text":63,"@type":64},"Solid tumors create an immunosuppressive microenvironment and show antigenic diversity, making it harder for CAR-T cells to penetrate the tumor. CAR-T cells also exhibit reduced proliferative activity and cytotoxicity in this setting.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What strategies are being developed to improve CAR-T performance against solid tumors?",{"text":68,"@type":64},"Researchers work on modifying the CAR structure and on enhancing CAR-T survival and efficiency in recognizing tumor antigens within solid tumors. The review also highlights ways to mitigate tumor microenvironment suppression and physical barriers.",{"name":70,"@type":61,"acceptedAnswer":71},"How can chemotherapy contribute to the efficacy of a combined CAR-T approach?",{"text":72,"@type":64},"Chemotherapy can be used before cell therapy to improve CAR-T cell engraftment. It may mitigate the suppressive impact of the tumor microenvironment, disrupt tumor stroma, and support greater immune-cell penetration, thereby improving survival and persistence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336964,1790165064,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Immunology, Immunotherapy (2025) 74:3 [https://doi.org/10.1007/s00262-024-03817-z](https://doi.org/10.1007/s00262-024-03817-z)  \nBreaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR‑T cells  \nMarat Khaliulin1 · Aygul Valiullina1 · Alexey Petukhov2 · Youyong Yuan4 · Sheila Spada3 · Emil Bulatov1,5,6  \nReceived: 30 March 2024 / Accepted: 22 August 2024 / Published online: 2 November 2024 © The Author(s) 2024  \nAbstract  \nThe use of chimeric antigen receptor (CAR)-T cells has enhanced the range of available therapeutic modalities in the context of cancer treatment. CAR-T cells have demonstrated considerable efficacy in the targeted eradication of blood cancer cells, thereby stimulating substantial interest in the advancement of such therapeutic approaches. However, the efficacy of CAR-T cells against solid tumor cells has been limited due to the presence of various obstacles. Solid tumors exhibit antigenic diversity and an immunosuppressive microenvironment, which presents a challenge for immune cells attempting to penetrate the tumor. CAR-T cells also demonstrate decreased proliferative activity and cytotoxicity. Furthermore, concerns exist regarding tumor antigen loss and therapy-associated toxicity. Currently, scientists are working to enhance the structure of the CAR and improve the survival and efficiency of CAR-T cells in recognizing tumor antigens in solid tumors. Chemotherapy drugs are frequently employed in the treatment of malignant neoplasms and can also be used prior to cell therapy to enhance CAR-T cell engraftment. Recent studies have demonstrated that chemotherapy drugs can mitigate the suppressive impact of TME, eliminate the physical barrier by destroying the tumor stroma, and facilitate greater penetration of immune cells and CAR-T cells into the tumor. This, in turn, increases their survival, persistence, and cytotoxicity, as well as affects the metabolism of immune cells inside the tumor. However, the effectiveness of the combined approach against solid tumors depends on several factors, including the type of tumor, dosage, population of CAR-T cells, and individual characteristics of the body. This review examines the principal obstacles to the utilization of CAR-T cells against solid tumors, proposes solutions to these issues, and assesses the potential advantages of a combined approach to radiation exposure, which has the potential to enhance the sensitivity of the tumor to other agents.  \nKeywords CAR-T cell therapy · Chemotherapy · Radiation therapy · Chimeric antigen receptor · Solid tumor  \n*  \n1  \n2  \n3  \n4  \n5  \n6  \nEmil Bulatov  \n[chembio.kazan@gmail.com](chembio.kazan@gmail.com)  \nInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia 420008  \nNazarbaev University, Qabanbay Batyr Ave 53, 010000 Astana, Kazakhstan  \nTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Via  \nE. Chianesi 53, 00144 Rome, Italy  \nSchool of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 511442, People’s Republic of China  \nShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia 117997  \nFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia 119048  \nIntroduction  \nThe ongoing advancement of science and technology is giving rise to the emergence of novel cancer treatment modalities that move away from the harmful systemic exposure associated with traditional therapies, toward more targeted and effective approaches. Conventional cancer treatments, including chemotherapy and surgery, are not without shortcomings. They can prove ineffective in cases of recurrent or resistant cancer, as well as in instances of distant metastases [1, 2] .  \nImmunotherapy, par","cbCaic83qaS7PhkQ","https://ap.wps.com/l/cbCaic83qaS7PhkQ","pdf",834558,12,"English","# Abstract\n# Introduction\n## Targeted oncology treatments and limitations of conventional therapy\n## Adoptive cell immunotherapy and CAR-based engineering\n## Clinical progress of CAR-T in oncohematological diseases\n## CAR structure and activation mechanism","[{\"question\":\"Why is CAR-T therapy less effective in solid tumors than in blood cancers?\",\"answer\":\"Solid tumors create an immunosuppressive microenvironment and show antigenic diversity, making it harder for CAR-T cells to penetrate the tumor. CAR-T cells also exhibit reduced proliferative activity and cytotoxicity in this setting.\"},{\"question\":\"What strategies are being developed to improve CAR-T performance against solid tumors?\",\"answer\":\"Researchers work on modifying the CAR structure and on enhancing CAR-T survival and efficiency in recognizing tumor antigens within solid tumors. The review also highlights ways to mitigate tumor microenvironment suppression and physical barriers.\"},{\"question\":\"How can chemotherapy contribute to the efficacy of a combined CAR-T approach?\",\"answer\":\"Chemotherapy can be used before cell therapy to improve CAR-T cell engraftment. It may mitigate the suppressive impact of the tumor microenvironment, disrupt tumor stroma, and support greater immune-cell penetration, thereby improving survival and persistence.\"}]","Breaking the Shield of Solid Tumors - a Combined Approach for Enhanced Efficacy of CAR-T Cells | PDF",1790017212,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55c7a6adb33c5ac4066b6c46cd6472be.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5498a506982083adf2d9db8976f98a70.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec2ee41c85b3403ef230a12352d56a09.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9aef33f89e27789a2b4d809c4909510.webp",980,1301]